The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The impact of MRD status by Clonoseq® in patients with MCL, DLBCL & FL treated with CAR-T therapy
Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, outlines the results of a study evaluating the predictive value of measurable residual disease (MRD) status measured with the clonoSEQ® assay in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL). Overall, the study found that MRD negativity was a predictor of good clinical response only in MCL, suggesting that better assays are needed in FL and DLBCL. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Consultancy; Miltenyi Biotec: Consultancy, Research Funding; Lilly Oncology: Consultancy, Honoraria; Epizyme: Consultancy; Bristol Myers Squibb: Consultancy; Incyte Corporation: Consultancy, Honoraria, Speakers Bureau; TG therapeutics: Consultancy; Kite Pharma: Consultancy.
